ClinicalTrials.gg
WithdrawnNCT03468829Updated Mar 11, 2019

Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection

A Phase 2 interventional study of ALX-0171 Dose 1 and ALX-0171 Dose 2 in Respiratory Syncytial Virus Lower Respiratory Tract Infection, sponsored by Ablynx, a Sanofi company. Withdrawn at 5 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-11.

Sponsored by Ablynx, a Sanofi company (part of Sanofi) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
ALX-0171 development program was stopped

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the antiviral effect and safety of inhaled ALX-0171 in adults diagnosed with respiratory syncytial virus (RSV) respiratory tract infection after hematopoietic stem cell transplantation (HSCT).

The secondary objective is to assess the clinical activity, pharmacokinetics (PK), virology, and immunogenicity of inhaled ALX 0171 in adults diagnosed with RSV respiratory tract infection after HSCT.

02

Conditions studied

  • Respiratory Syncytial Virus Lower Respiratory Tract Infection
03

In context

Lead sponsor

Ablynx, a Sanofi company is the lead sponsor of 25 studies on the registry; none are open to participants now.

First submitted before Ablynx became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has received an using any conditioning regimen and for any underlying etiology (i.e., subject has received an autologous or allogeneic HSCT)
  2. Subject is clinically diagnosed with RSV infection with new onset or acute worsening
  3. Symptoms likely related to RSV infection have appeared within 5 days of screening and their severity requires initial or maintained hospitalization.
  4. Documented RSV infection in the upper respiratory tract (URT)
  5. Subject has:

    • Diagnosis of RSV lower respiratory tract (LRT) disease or
    • Diagnosis of RSV URT disease with high risk of progression to lower respiratory tract infection (LRTI)

Others as defined in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Subject has bacteremia or fungemia within 7 days of screening
  2. Subject has clinically significant bacterial, fungal or viral pneumonia
  3. Subject presents evidence of shock requiring intensive care unit (ICU) monitoring and/or vasopressor treatment
  4. Subject requires or is expected to require invasive mechanical ventilation or intensive non-invasive respiratory support. Standard oxygen supplementation up to 6 L/minute is permitted provided it can be interrupted for the duration of study drug administration.

Others as defined in the protocol

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    ALX-0171 Dose 1

    Biological: ALX-0171 Dose 1

  • Experimental
    ALX-0171 Dose 2

    Biological: ALX-0171 Dose 2

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalALX-0171 Dose 1

    Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days

  • BiologicalALX-0171 Dose 2

    Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days

  • BiologicalPlacebo

    Oral inhalation of Placebo once daily for a maximum of 14 days

06

What researchers measure

Primary outcomes

  1. Time-weighted average change from baseline in log10 RSV nasal viral load

    Time frame: From Day 1 to Day 7

Secondary outcomes

  1. Safety as measured by the incidence of treatment-emergent (serious) adverse events

    Time frame: From Screening to Day 42

  2. Nasal RSV load parameter: time to undetectable shedding

    Time frame: From Day 1 to Day 42

  3. Clinical stabilization (defined as respiratory rate <25/minute and stable oxygen saturation >92% on room air for at least 12 hours)

    Time frame: From Day 1 to Day 42

  4. Number of days without oxygen or with oxygen supplementation

    Time frame: From Day 1 to Day 42

  5. Progression to lower respiratory tract (LRT) disease in subjects presenting with upper respiratory tract infection (URTI) at baseline

    Time frame: From Day 1 to Day 42

  6. Concentration of ALX-0171 in serum

    Measurement of ALX-0171 serum concentration at different time points from baseline until Day 14.

    Time frame: Day 1 to Day 14

  7. Immunogenicity as measured by the concentration of anti-ALX 0171 antibodies in serum

    Time frame: From Day 1 to Day 42

07

Study locations

5 sites
  • Investigator site
    Darlinghurst, Australia
  • Investigator site
    Westmead, Australia
  • Investigator site
    Leuven, Belgium
  • Investigator site 1
    Valencia, Spain
  • Investigator site 2
    Valencia, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2019; primary completion for May 2020, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2018
First posted
Mar 19, 2018
StartEst.
Feb 2019
Primary completionEst.
May 2020
CompletionEst.
May 2020
Last update
Mar 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03468829
Responsible party
Sponsor
First posted
Mar 19, 2018
Start date
Feb 2019 (estimated)
Primary completion
May 2020 (estimated)
Completion
May 2020 (estimated)
Last update
Mar 11, 2019

Study contacts

Ablynx Clinical Department
study director · Ablynx, a Sanofi company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gontivimab

Start the discussion